USFDA completes inspection at Biocon’s Insulins facilities in Malaysia

08 Jul 2019 Evaluate

US Food and Drug Administration (USFDA) has completed inspection at Biocon’s Insulin Glargine Drug Substance, Drug Product and Device assembly facilities in Malaysia. A per-approval inspection by USFDA was carried out from June 24 and July 5, 2019. The inspection across these 3 units concluded with 12 observations issued on the Form 483.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

394.65 6.90 (1.78%)
02-Jan-2026 14:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1722.00
Dr. Reddys Lab 1252.10
Cipla 1508.10
Zydus Lifesciences 914.60
Lupin 2103.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×